A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost ...

The Centers for Medicare and Medicaid Services said Tuesday it seeks to lower Medicare costs for 16 medications by negotiating with their manufacturers. Among them is Biktarvy, a drug taken after HIV ...

NEW YORK (AP) — Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that allows the federal government to haggle ...

Sound policy is best developed through legislation because it requires group decisions.

Beginning this year, Medicare's new negotiated drug prices could cut prescription costs in half for millions of seniors, a ...

The first 10 prescription drugs subject to Medicare price negotiations go into effect on Jan. 1. Medicare beneficiaries will see substantially lower costs for those treatments in 2026, according to a ...

Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare. The Centers for Medicare & Medicaid Services (CMS), the federal agency that ...

President Donald Trump has said that Americans are now paying or will pay "the lowest price anywhere in the world for drugs," thanks to the administration’s negotiations with pharmaceutical companies.

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare. Medicare targets 15 more drugs for price negotiations -- including ...

In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming ...

While the 15 medications selected for the latest round of the federal government’s drug price negotiation program will face steep cuts in what Medicare will pay, the financial impact to pharmaceutical ...